Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVE-2: Avelumab and Cetuximab Rechallenge in mCRC
NCT05291156Phase 2Recruiting
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avelumab in metastatic colorectal cancer (mCRC), sponsored by University of Campania Luigi Vanvitelli. Started Jul 2022; status: recruiting.
02
Drugs
avelumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05291156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291156.